Models of CMV infection

Drug Discovery Today: Disease Models

Volumn 3, Issue 1, 2006, Pages 91-96

  Wynn, Katherine K ^a   Khanna, Rajiv ^a  

^a QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CIDOFOVIR; DNA VACCINE; FOSCARNET; GANCICLOVIR;

CELLULAR IMMUNITY; CLINICAL FEATURE; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; DISEASE ASSOCIATION; GUINEA PIG; HERPES VIRUS; HUMORAL IMMUNITY; IMMUNE DEFICIENCY; IMMUNE SYSTEM; IMMUNOCOMPETENT CELL; IN VITRO STUDY; INOCULATION; MOLECULAR MECHANICS; MOUSE; NONHUMAN; PATHOGENESIS; PRIMATE; REVIEW; SPECIES DIFFERENCE; SWINE; VIRUS CELL INTERACTION; VIRUS REPLICATION; VIRUS TRANSMISSION; VIRUS VIRULENCE;

EID: 33645867362     PISSN: 17406757     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ddmod.2006.03.011     Document Type: Review

References (41)

1. Gandhi M.K., and Khanna R. Human cytomegalovirus: clinical aspects, immune regulation, and emerging treatments. Lancet Infect. Dis. 4 (2004) 725-738
2. Stratton K.R., et al. Vaccines for the 21st Century: A Tool for Decision Making (2000), National Academy Press
3. Quinnan Jr. G.V., et al. Comparative virulence and immunogenicity of the Towne strain and a nonattenuated strain of cytomegalovirus. Ann. Intern. Med. 101 (1984) 478-483
4. Plotkin S.A., et al. Candidate cytomegalovirus strain for human vaccination. Infect. Immun. 12 (1975) 521-527
5. Cha T.A., et al. Human cytomegalovirus clinical isolates carry at least 19 genes not found in laboratory strains. J. Virol. 70 (1996) 78-83
6. Brown J.M., et al. Dramatic interstrain differences in the replication of human cytomegalovirus in SCID-hu mice. J. Infect. Dis. 171 (1995) 1599-1603
7. Michel D., et al. Aciclovir selects for ganciclovir-cross-resistance of human cytomegalovirus in vitro that is only in part explained by known mutations in the UL97 protein. J. Med. Virol. 65 (2001) 70-76
8. Cho H.I., et al. Generation of cytotoxic T lymphocytes specific for human cytomegalovirus using dendritic cells in vitro. J. Immunother. 24 (2001) 242-249
9. Heine A., et al. Transfection of dendritic cells with in vitro-transcribed CMV RNA induces polyclonal CD8(+)- and CD4(+)-mediated CMV-specific T cell responses. Mol. Ther. 13 (2006) 280-288
10. Manley T.J., et al. Immune evasion proteins of human cytomegalovirus do not prevent a diverse CD8+ cytotoxic T-cell response in natural infection. Blood 104 (2004) 1075-1082
11. Khan N., et al. Identification of cytomegalovirus-specific cytotoxic T lymphocytes in vitro is greatly enhanced by the use of recombinant virus lacking the US2 to US11 region or modified vaccinia virus Ankara expressing individual viral genes. J. Virol. 79 (2005) 2869-2879
12. Sampaio K.L., et al. Human cytomegalovirus labeled with green fluorescent protein for live analysis of intracellular particle movements. J. Virol. 79 (2005) 2754-2767
13. Reddehase M.J. Antigens and immunoevasins: opponents in cytomegalovirus immune surveillance. Nat. Rev. Immunol. 2 (2002) 831-844
14. Johnson K.P. Mouse cytomegalovirus: placental infection. J. Infect. Dis. 120 (1969) 445-450
15. Enders A.C. A comparative study of the fine structure of the trophoblast in several hemochorial placentas. Am. J. Anat. 116 (1965) 29-67
16. Tsutsui Y., et al. Neuropathogenesis in cytomegalovirus infection: indication of the mechanisms using mouse models. Rev. Med. Virol. 15 (2005) 327-345
17. Hengel H., et al. Immune evasion by cytomegalovirus - survival strategies of a highly adapted opportunist. Trends Microbiol. 6 (1998) 190-197
18. Boppana S.B., and Britt W.J. Antiviral antibody responses and intrauterine transmission after primary maternal cytomegalovirus infection. J. Infect. Dis. 171 (1995) 1115-1121
19. Li C.R., et al. Recovery of HLA-restricted cytomegalovirus (CMV)-specific T-cell responses after allogeneic bone marrow transplant: correlation with CMV disease and effect of ganciclovir prophylaxis. Blood 83 (1994) 1971-1979
20. Rapp M., et al. Identification of the murine cytomegalovirus glycoprotein B gene and its expression by recombinant vaccinia virus. J. Virol. 66 (1992) 4399-4406
21. Jonjic S., et al. Antibodies are not essential for the resolution of primary cytomegalovirus infection but limit dissemination of recurrent virus. J. Exp. Med. 179 (1994) 1713-1717
22. Schleiss M.R. Nonprimate models of congenital cytomegalovirus (CMV) infection: gaining insight into pathogenesis and prevention of disease in newborns. ILAR J. 47 (2006) 65-72
23. Schleiss M.R., et al. Preconception vaccination with a glycoprotein B (gB) DNA vaccine protects against cytomegalovirus (CMV) transmission in the guinea pig model of congenital CMV infection. J. Infect. Dis. 188 (2003) 1868-1874
24. Schleiss M.R., et al. Protection against congenital cytomegalovirus infection and disease in guinea pigs, conferred by a purified recombinant glycoprotein B vaccine. J. Infect. Dis. 189 (2004) 1374-1381
25. Brideau R.J., et al. Broad-spectrum antiviral activity of PNU-183792, a 4-oxo-dihydroquinoline, against human and animal herpesviruses. Antiviral Res. 54 (2002) 19-28
26. Buerger I., et al. A novel nonnucleoside inhibitor specifically targets cytomegalovirus DNA maturation via the UL89 and UL56 gene products. J. Virol. 75 (2001) 9077-9086
27. Schleiss M.R., et al. The non-nucleoside antiviral, BAY 38-4766, protects against cytomegalovirus (CMV) disease and mortality in immunocompromised guinea pigs. Antiviral Res. 65 (2005) 35-43
28. Drew, W.L. (2005) Is combination antiviral therapy for CMV superior to monotherapy? J. Clin. Virol. 10.1016/j.jcv.2005.09.021 (http://www.sciencedirect.com/science/journal/13866532)
29. Limaye A.P., et al. Emergence of ganciclovir-resistant cytomegalovirus disease among recipients of solid-organ transplants. Lancet 356 (2000) 645-649
30. Yue Y., et al. Antibody responses to rhesus cytomegalovirus glycoprotein B in naturally infected rhesus macaques. J. Gen. Virol. 84 (2003) 3371-3379
31. Lockridge K.M., et al. Pathogenesis of experimental rhesus cytomegalovirus infection. J. Virol. 73 (1999) 9576-9583
32. Kaur A., et al. Cytotoxic T-lymphocyte responses to cytomegalovirus in normal and simian immunodeficiency virus-infected rhesus macaques. J. Virol. 70 (1996) 7725-7733
33. Swanson R., et al. Characterization of rhesus cytomegalovirus genes associated with anti-viral susceptibility. Virology 240 (1998) 338-348
34. Kropff B., and Mach M. Identification of the gene coding for rhesus cytomegalovirus glycoprotein B and immunological analysis of the protein. J. Gen. Virol. 78 (1997) 1999-2007
35. Marshall G.S., et al. Antibodies to the major linear neutralizing domains of cytomegalovirus glycoprotein B among natural seropositives and CMV subunit vaccine recipients. Viral Immunol. 13 (2000) 329-341
36. Elkington R., et al. Cross-reactive recognition of human and primate cytomegalovirus sequences by human CD4 cytotoxic T lymphocytes specific for glycoprotein B and H. Eur. J. Immunol. 34 (2004) 3216-3226
37. Alford C.A., and Britt W.J. Cytomegalovirus. In: Roizman B., et al. (Ed). The Human Herpesviruses (1993), Raven Press
38. London W.T., et al. Experimental congenital disease with simian cytomegalovirus in rhesus monkeys. Teratology 33 (1986) 323-331
39. Tarantal A.F., et al. Neuropathogenesis induced by rhesus cytomegalovirus in fetal rhesus monkeys (Macaca mulatta). J. Infect. Dis. 177 (1998) 446-450
40. Lan, P. et al. (2006) Reconstitution of a functional human immune system in immunodeficient mice through combined human fetal thymus/liver and CD34+ cell transplantation. Blood. 10.1182/blood-2005-11-4388 (http://www.bloodjournal.org)
41. Traggiai E., et al. Development of a human adaptive immune system in cord blood cell-transplanted mice. Science 304 (2004) 104-107